The global breast biopsy device market is experiencing robust growth, driven by increasing awareness of early breast cancer detection and continuous improvements in diagnostic technologies. The market was valued at USD 2.7 billion in 2025 and is projected to reach USD 4.5 billion by the end of 2035, representing a compound annual growth rate (CAGR) of 5.8% over the forecast period from 2026 to 2035.
This growth trajectory is driven by the expansion of screening programs, the growing global female population, and the shift toward minimally invasive diagnostic procedures. Technological innovations and the wider adoption of image-guided biopsy techniques continue to drive market trends in both developed and developing healthcare systems.
Demand for breast biopsy devices in the industry
The breast biopsy device market includes medical instruments and related systems used to extract tissue samples from breast lesions for pathological examination. These devices play a critical role in confirming malignancies, guiding treatment decisions, and improving patient outcomes through accurate diagnosis.
Demand for breast biopsy devices in the industry is growing due to a number of favorable characteristics. These devices are widely viewed as a cost-effective alternative to surgical biopsy, significantly reducing hospital stays and procedure costs. Ease of use, particularly with image-guided and minimally invasive systems, has increased the efficiency of the procedure for physicians and patient comfort. Furthermore, many biopsy consumables and reagents have a long shelf life, allowing medical facilities to effectively manage inventory.
Increased emphasis on early cancer detection, coupled with national screening programs and advances in imaging techniques, has made breast biopsy devices essential components of modern diagnostic algorithms.
Breast Biopsy Devices Market: Growth Drivers and Key Restraining Factors
Growth factors –
- Rising incidence of breast cancer and chronic diseases.
The increasing incidence of breast cancer worldwide has increased the demand for reliable diagnostic tools. Early detection initiatives and routine screening programs have significantly expanded the use of biopsy devices, particularly in high-risk groups. - Technological advances and innovation.
Continuous innovations in biopsy techniques, such as vacuum-assisted biopsy and image-guided biopsy, have increased diagnostic accuracy and reduced the invasiveness of the procedure. Integration with advanced imaging technologies has increased physician confidence and expanded the scope of clinical applications. - Cost-effectiveness and the shift to outpatient treatment.
Breast biopsy devices enable minimally invasive procedures in an outpatient setting. This reduces overall healthcare costs and aligns with the growing popularity of outpatient treatment, further accelerating market adoption.
Restraint –
- Limited access in resource-poor settings.
Despite technological advances, access to modern breast biopsy devices remains limited in some regions due to the high cost of equipment, a shortage of qualified specialists, and inadequate healthcare infrastructure, hindering wider market penetration.
You can request a sample via the link: https://www.researchnester.com/sample-request-8106
Breast Biopsy Devices Market: Segment Analysis
Segment analysis by product –
- Vacuum-assisted biopsy (VAB) devices
are widely used due to their ability to collect large tissue samples with fewer injections. Demand is driven by their high diagnostic accuracy and reduced need for repeat procedures, making them preferred in complex cases. - Core needle biopsy (CNB) devices
remain a standard diagnostic tool due to their optimal combination of accuracy, affordability, and clinical reliability. Their widespread availability maintains stable market demand across a variety of medical settings. - Fine-needle aspiration biopsy (FNAB) devices
are widely used for the preliminary assessment and investigation of cystic lesions. Their minimally invasive nature and rapid results facilitate their consistent use, particularly in outpatient clinics. - Biopsy needles.
This segment benefits from consistent demand driven by the need for single-use biopsy needles. Continuous improvements in needle design enhance patient comfort and procedure efficiency. - Guidance systems.
Guidance systems, including ultrasound and stereotactic platforms, play a vital role in precise targeting of lesions. Growth in this segment is driven by the increasing use of image-guided diagnostics. - Reagents and kits.
Reagents and kits support subsequent diagnostic processes. Their continued use in pathological analysis ensures stable demand, supported by advances in molecular and histological diagnostics.
Segment analysis by application area –
- Early cancer detection.
This app is a market leader as healthcare systems prioritize early detection to improve survival rates and simplify treatment. - for differential diagnosis
and biopsy play a crucial role in distinguishing between benign and malignant tumors, which leads to high demand for them in diagnostic imaging centers. - Tumor identification
. Accurate tumor characterization facilitates treatment planning and ensures the sustainable use of advanced biopsy technologies. - Lymph node biopsy.
The increasing use of biopsy devices for staging and metastasis assessment has expanded their role beyond primary tumor evaluation. - Relapse monitoring.
Ongoing post-treatment patient monitoring confirmed the need for repeat and control biopsies.
Segment analysis by end users –
- Hospitals
represent an important end-user group due to their access to advanced imaging systems, skilled personnel, and comprehensive oncology services. - Diagnostic centers and imaging clinics.
These facilities are experiencing rapid growth as outpatient diagnostics expands and patients seek faster, less invasive screening options. - Academic and research institutions.
Research institutions are driving market growth through clinical trials, technology validation, and innovation in biopsy techniques. - Outpatient surgical centers.
The transition to same-day procedures has led to increased use of outpatient breast biopsy devices.
Breast Biopsy Devices Market: Regional Analysis
North America
North America dominates the breast biopsy market due to high screening rates, a developed healthcare infrastructure, and the rapid adoption of innovative diagnostic technologies. Favorable reimbursement systems and extensive outreach programs continue to drive demand in the region.
Europe
Europe is demonstrating steady growth, supported by government cancer screening initiatives and increasing investment in diagnostic imaging. The region benefits from active clinical research and continued demand for minimally invasive diagnostic solutions.
Asia-Pacific Region (APR)
The Asia-Pacific region is experiencing rapid market growth, driven by improved access to healthcare, increased awareness of cancer, and expanded diagnostic capabilities. Increased investment in medical infrastructure and the growing adoption of advanced diagnostic tools are key drivers of regional growth.
Leading players in the breast biopsy device market
The largest players in the global breast biopsy device market include Danaher Corporation (CR Bard/Bard Biopsy), BD, Argon Medical Devices, Medtronic, Cook Medical, Siemens Healthineers AG, GE HealthCare, Planmed Oy, Sterylab Srl, CareFusion Corporation, and Intact Medical Corporation. These organizations emphasize continuous technological development, partnerships, and regional market expansion strategies to enhance their competitiveness and meet the evolving needs of clinical diagnostics.
A detailed report is available at: https://www.researchnester.com/reports/breast-biopsy-devices-market/8106
Research Nester Analytics is a leading provider of strategic marketing research and consulting services. We provide objective, unrivaled market data and industry analysis, helping industries, conglomerates, and executives make informed decisions regarding future marketing strategy, expansion, and investment. We believe that any business can expand its horizons with the right guidance at the right time. Our unconventional approach helps clients navigate future uncertainties and market dynamics.
For more information, please contact us:
AJ Daniel
Email: info@researchnester.com
US Phone: +1 646 586 9123
UK phone: +44 203 608 5919
